Immune activation antibody and application thereof

An immune activation, antibody technology, applied in the direction of antibodies, immunoglobulins, antibody medical components, etc., can solve the problems of normal tissue damage and side effects, and achieve the effect of avoiding damage and side effects and having a good application prospect.

Inactive Publication Date: 2021-06-15
SHENZHEN KANGJUZHENG PHARMA TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effect of this patented method for making certain types of molecules that can be useful against cancer tumors without causing harmful damage during treatment was achieved by providing them with specific parts called labeled monoclonal antibodies - these were made from different sources like animal blood serums or human plasma. These labeled antibods had some part they could bind specifically onto their own targets while others didn't. This led researchers to develop ways to use those specialized ones instead of just treatments themselves.

Problems solved by technology

The technical problem addressed in this patented text relates to reducing or preventing unwanted inflammatory responses caused by certain types of stimulants used during treatment for cancer patients without causing harmful side effectings that could affect healthy organs nearby.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune activation antibody and application thereof
  • Immune activation antibody and application thereof
  • Immune activation antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0155] The synthetic method of compound 1, comprises the steps:

[0156] Dissolve 2.37 g of compound Pro-1 and 1.2 g of propyne bromide in 50 mL of DMF, and add 1.5 g of K 2 CO 3 , and stirred at room temperature for 12 hours. After filtration, the filtrate was distilled under reduced pressure (less than 60°C) to remove the solvent, and the residue was added with 25 mL of concentrated hydrochloric acid, and stirred at room temperature for 10 hours. reactant with K 2 CO 3 Neutralize to pH 7, precipitate a crude solid product, dissolve in methanol, separate by silica gel column chromatography (methanol: dichloromethane = 1:10 volume ratio), collect the product solution, concentrate under reduced pressure to remove the solvent, and obtain a white solid product which is the compound 1. ESI-MS: m / z=263.10[M+H] + .

[0157] The reaction formula of synthetic compound 1 by compound Pro-1 is as follows:

[0158]

[0159] The synthesis method of compound 2 and compound 3 is ba...

Embodiment 1

[0330] TLR7 Activation Detection of the Compound of Example 1 (HEK-BlueTM Detection)

[0331] Take HEK-Blue TMh TLR7 cells in the logarithmic growth phase (purchased from InvivoGen), discard the growth medium (Gibco, C11995500BT, Invivo Gen, ant-nr), and take an appropriate amount of 37°C PBS (Hyclone, SH30256.01) Wash the cells twice by lightly rinsing, and discard the PBS. Add 2-5mL 37°C PBS, incubate for 1-2min, scrape off the cells with a cell scraper, and blow gently to disperse them into a single-cell suspension. The cells were counted and the cell concentration was calculated using a hemocytometer, and the cell suspension was adjusted to 2.5×104 / 180 μL per well using HEK-BlueTM Dectetion solution (purchased from Invivo Gen) for cell plating on a 96-well cell culture plate. HEK-BlueTM hTLR7 cells were stimulated according to the compound or drug concentration (for example, 0.01 μM, 0.1 μM, 1 μM, 5 μM, 15 μM, 30 μM, 40 μM), and three replicate wells were set for each con...

Embodiment 2

[0332] Example 2 Detection of the TLR7 agonist release effect of each immune-activating antibody

[0333] Take each immune-activating antibody and add it to HER2-positive SKBR3 (10 5 1) cells in RPMI1640 medium. After mixing and culturing for 12 hours, each supernatant was taken out, and the TLR7 activation effect was tested according to the method in Example 1. The result is as figure 2 with image 3 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and particularly relates to an immune activation antibody and application thereof. The immune activation antibody provided by the invention comprises an antibody and an immune activator which are coupled through a coupling chain, and can be used for preparing antitumor drugs, antiviral drugs, immunomodulatory drugs and/or preparations for eliminating target proteins. According to the invention, the antibody and the immune activator are coupled through the coupling chain, such that a series of the immune activation antibodies targeting the specific tissue, the focus and the target spot can be formed, the local targeting immune activation effect can be achieved, the negative influence of TLR activation on the normal tissue can be solved, and has good specific immune regulation and treatment effect.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner SHENZHEN KANGJUZHENG PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap